INSUBCONTINENT EXCLUSIVE:
in the field of vaccine development.Researchers at McGill University in Canada carried out a survey of 28 experts working in vaccinology in
in the field."Experts in our survey offered forecasts on vaccine development that were generally less optimistic than the timeline of early
2021 offered by US public officials," Jonathan Kimmelman, a professor at McGill University, said in a statement."In general they seem to
believe that a publicly available vaccine next summer is the best-case scenario with the possibility that it may take until 2022," said
some false starts before an effective vaccine is available."The experts we surveyed believe that there is a 1 in 3 chance that the vaccine
will receive a safety warning label after approval, and a 4 in 10 chance that the first large field study will not report efficacy," added
Patrick Kane, the lead author of the paper, a postdoctoral fellow at McGill University.The study also showed that about one-third of those
will receive a boxed warning from the FDA to highlight serious or life-threatening adverse reactions, the researchers said.Also, the first
large field trial in the US and/or Canada will report a null or negative result in terms of efficacy, they said."Our study finds that
experts are largely in agreement about the timeline for a SARS-CoV-2 vaccine," said Stephen Broomell, an associate professor at Carnegie
Mellon University in the US."While this does not track with many overly optimistic government projections, it reflects a belief that
